Canaccord Adams maintains a 'Buy' on BioMimetic Therapeutics (Nasdaq: BMTI), lowers price target to $10.50 from $17.50.

Canaccord analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE